It is part of the PROFIT Project (Personalizing the Approach to Frail Oncology Patients through Assessment and Individualized Intervention), an innovative initiative focused on providing comprehensive care for oncology patients experiencing frailty.

The collaboration will focus on several key areas of mutual interest in microbiology in particular antimicrobial resistance and stewardship.

This is a structured system that prioritizes projects with the greatest potential to ensure their viability and maximize the chances of success in their clinical application and commercialization, with a focus on benefiting patients.

The data compromised are identification data such as name, surname and ID, as well as contact information, such as email or telephone.

The study seeks to better understand blood disorders in children and young people, analyzing the role of immunological alterations to improve diagnosis and treatment.

130 schoolchildren visited the VHIR laboratories, where different scientists explained their research areas with the aim of demystifying the profession.

Funded by the European Union, this project coordinated by the Vall d'Hebron Research Institute (VHIR) seeks to develop more effective therapies by creating new combinations of existing drugs

Aquest conveni amb un dels centres més potents del món té com a objectiu fomentar l'intercanvi de coneixements, recursos i experiències per millorar la formació en salut i la pràctica clínica al Centre de Simulació Clínica Avançada.

The doctoral training program of excellence led by the UAB TOUCH MSCA-COFUND, focused on the field of mental health, opens its second call until March 31.

VHIR presents an innovative tool that streamlines the search for animal models, fostering collaboration between researchers and advancing scientific research based on the principles of the 3Rs.

Within the framework of the Strategic Action in Health 2024 call, funding has also been granted for two other projects in calls for Technological Development in Health and Independent Clinical Research.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

The study, which involved Vall d'Hebron, developed an action plan to efficiently allocate resources to patients most at risk of suffering this complication.

A study led by Dr. Manel Mendoza from Vall d’Hebron shows that studying the levels of placental markers is as effective as Doppler ultrasounds, the standard method for classifying the risk of pregnancies with low birth weight fetuses.

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

The initiative seeks to raise awareness of the disease and promote the well-being of those affected, while fostering empathy and scientific vocations among young people.

The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.

You can now register for the Master's Degree in Translational Biomedical Research, the Master's Degree in Clinical Trial Management and Coordination and, as a novelty, the Master's Degree in Health Innovation and Entrepreneurship.

The EXPOSIM project will investigate the impact of environmental stressors such as pollution, noise and aeroallergens on immune-mediated diseases.

In light of this evidence, hospitals such as Vall d'Hebron have already started to include warnings about environmental pollution in their hospital discharge plans after a myocardial infarction.

The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.

The Association for the Information and Research of Familial Hypomagnesemia, once again, has shown its solidarity with a donation of €19,000.

VHIR collaborates in the development of nanoGLA, an innovative nanotechnology therapy to treat Fabry disease. It has demonstrated high efficacy in preclinical studies, highlighting its effectiveness in addressing neurological manifestations.